Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.680
+0.180 (12.00%)
At close: Feb 25, 2026, 4:00 PM EST
1.690
+0.010 (0.60%)
After-hours: Feb 25, 2026, 5:21 PM EST
Acrivon Therapeutics Employees
As of December 31, 2024, Acrivon Therapeutics had 78 total employees, including 75 full-time and 3 part-time employees. The number of employees increased by 17 or 27.87% compared to the previous year.
Employees
78
Change (1Y)
17
Growth (1Y)
27.87%
Revenue / Employee
n/a
Profits / Employee
-$1,048,090
Market Cap
53.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 78 | 17 | 27.87% | 75 | 3 |
| Dec 31, 2023 | 61 | 17 | 38.64% | 58 | 3 |
| Sep 30, 2023 | 59 | 17 | 40.48% | 56 | 3 |
| Jun 30, 2023 | 53 | 17 | 47.22% | 50 | 3 |
| Mar 31, 2023 | 48 | 12 | 33.33% | 45 | 3 |
| Dec 31, 2022 | 44 | - | - | 41 | 3 |
| Sep 30, 2022 | 42 | - | - | 39 | 3 |
| Jun 30, 2022 | 36 | - | - | 35 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Kezar Life Sciences | 55 |
| NextCure | 43 |
| Plus Therapeutics | 21 |
| NeurAxis | 21 |
| CervoMed | 15 |
| Apollomics | 13 |
| OS Therapies | 5 |
ACRV News
- 1 day ago - Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 days ago - Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - GlobeNewsWire
- 7 days ago - Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - GlobeNewsWire
- 4 weeks ago - Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - GlobeNewsWire
- 6 weeks ago - Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls - Benzinga
- 6 weeks ago - Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - GlobeNewsWire
- 7 weeks ago - Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire
- 2 months ago - UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire